Navigation Links
Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
Date:12/14/2011

the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.

 Champions Oncology, Inc.Reconciliation of GAAP to Non-GAAP Net Loss(Amounts in thousands except for loss per share amounts) 

Three Months Ended

October 31,

 

Six Months Ended

October 31, 

2011

2010

 

2011

2010Net loss attributable to Champions – GAAP

($2,349)

($54)

 

($4,386)

($645)Less:

Stock-based compensation

 

855

 

197

 

 

1,867

 

367Net income (loss) attributable to Champions-non-GAAP:

($1,494)

$143

 

($2,159)

($278) 

Net income (loss) per common share attributable to Champions – non GAAP:

 

 

 

 

 Basic and diluted

($0.03)

$0.00

 

($0.05)

($0.01) 

CONTACT:
Susan Foreman
Champions Oncology, Inc.
+1-410-369-0365


'/>"/>
SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Champions CFO Resigns
10. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
11. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Pa. , July 31, 2014   Auxilium ... fully integrated specialty biopharmaceutical company, today announced that the ... 2014 on Thursday, August 7, 2014 before the opening ... conduct a conference call that day at 8:30 a.m. ... quarter of 2014. The presentation slides to be used ...
(Date:7/31/2014)... Fla. , July 31, 2014 Rock ... today that it has initiated the development of its ... ; and that it has selected Quotient Clinical, The ... Kingdom (UK) to run its early development ... Clinical Trial Application (CTA) by the end of the ...
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... Reportlinker.com announces that a new market ... Triple Analysis: Lymphoma, Prostate ... http://www.reportlinker.com/p0284719/Triple-Analysis-Lymphoma-Prostate-Cancer-and-Antibodies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology This triple analysis ... both Lymphoma and Prostate Cancer and by ...
... CYBX ), a global leader in epilepsy management, today ... Conference on Wednesday, June 8, 2011, in New York. ... Financial Officer, will speak to the attendees of the conference ... the presentation can be accessed by clicking on the Investor ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 2Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 3Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 4Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 5
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... study, researchers at University Hospitals Rainbow Babies & Children,s ... at greater risk for death on a commercial airline ... worldwide between January 2010 and June 2013 and found ... age of 2. , The study was conducted ... of an in-flight pediatric fatality onboard commercial airline flights ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2
... Mayo is the first organization approved for three specialties ... The American Board of Family Medicine (ABFM), ... American Board of Pediatrics (ABP)—the nation,s three largest physician certifying ... Sponsor of Maintenance of Certification (MOC) activities. Mayo Clinic,s rigorous attention ...
... , SAN DIEGO , Jan. 27 ... that the Company will report its fourth quarter and year-end 2009 ... 2010.  Neurocrine will then host a  live conference call and webcast ... afternoon, February 3, 2010 at 5:00 p.m. Eastern ...
... a leading source of adult stem cells, which are ... the cells is an arduous and often painful process. ... as adipose tissue, may be a promising new source ... and progenitor cells (HSPCs), according to a study ...
... United States has an inefficient and expensive health care system, ... care system detailed in a new study in the ... No. 2). According to the authors of ... Health Care System" from Ben-Gurion University of the Negev (BGU) ...
... of Medicine has been awarded six Department of ... grants for innovative medical research. The grants, totaling ... field of breast cancer. Case Western ... awards and three Idea Awards. The three postdoctoral ...
... few anti-spasticity medications used for children with cerebral palsy ... according to a new review of scientific literature headed ... by a national panel of interdisciplinary experts nationwide. ... release a new practice guideline on effective treatments. Dr. ...
Cached Medicine News:Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 2Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 3Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 4Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 5Health News:Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results 2Health News:Fat tissue may be a source of valuable blood stem cells, study says 2Health News:Fat tissue may be a source of valuable blood stem cells, study says 3Health News:Integrating private insurance with public health would improve US health care -- study 2Health News:Case Western Reserve receives $2.8 million to further breast cancer research 2Health News:Anti-spasticity medications need further research 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: